CTIT is a common and clinically consequential hematologic toxicity in patients with solid tumors. Chemotherapy, radiotherapy, and targeted agents can all suppress the bone marrow’s ability to produce platelets, the small cell fragments that form clots and prevent hemorrhage. When platelet counts fall below safe thresholds, oncologists are frequently forced to postpone or reduce doses of anti-cancer drugs, compromising the very treatment meant to control the tumor. In severe cases, spontaneous bleeding can become life-threatening. Platelet transfusions and standard TPO-RA monotherapy help many patients, but a subset remains refractory, with counts that stay dangerously low despite every conventional measure.

The research team, led by Lin-Ya Wang and Fei-Fei Tang of the Peking University Institute of Hematology, set out to test whether adding ATRA to continued TPO-RA therapy could break through this resistance. Their rationale rests on platelet biology: TPO-RAs such as eltrombopag and romiplostim stimulate thrombopoietin receptors on megakaryocytes, the large bone marrow cells that shed platelets into the bloodstream, while ATRA is thought to promote megakaryocyte maturation and platelet production through complementary pathways, including retinoid signaling and effects on the bone marrow microenvironment. Combining the two agents, the investigators reasoned, might attack the problem from two directions at once.

The study retrospectively analyzed 28 patients with refractory CTIT, defined as grade 2 or worse thrombocytopenia according to the CTCAE v5.0 criteria despite prior TPO-RA therapy. All patients were treated at Peking University People’s Hospital between August 2023 and May 2025. Each received oral ATRA at a dose of 25 milligrams per square meter of body surface area daily for six weeks, alongside continued TPO-RA treatment. The severity of the starting condition was sobering: the median baseline platelet count was just 13 × 10⁹ per liter, with individual values ranging from a perilous 2 × 10⁹ to 69 × 10⁹ per liter. Counts at that level leave patients exposed to serious bleeding risk and effectively rule out continued cancer therapy.

The results were unambiguous. Platelet counts climbed steadily from baseline after treatment began, with median elevations of +17 × 10⁹ per liter by day 14 (P = 3.05 × 10⁻⁵), +36 × 10⁹ per liter by day 28 (P = 9.54 × 10⁻⁷), and +59 × 10⁹ per liter by day 42 (P = 7.45 × 10⁻⁹). By the end of the observation window, the median patient had gained nearly five times their starting platelet count. Twelve patients, or 42.9 percent, achieved a complete response, defined as recovery to normal platelet levels, while another seven patients, 25.0 percent, achieved a partial response. The overall response rate stood at 67.9 percent, meaning roughly two of every three patients who had failed standard therapy regained usable platelet counts. The median time to complete response was 31 days, with responses occurring as early as 12 days and as late as 40 days after starting the combination.

Safety data were equally encouraging. ATRA is not a benign molecule; it carries known risks of liver enzyme elevation, headache, and, in the setting of acute promyelocytic leukemia, a potentially dangerous complication called differentiation syndrome. Yet in this population, the combination was well tolerated. Only four patients, 14.3 percent, developed elevated liver enzymes, three of them grade 1 and one grade 2, and three patients, 10.7 percent, experienced mild, grade 1 nausea. Critically, no grade 3 or higher adverse events were recorded, no thrombotic events occurred, and no patient developed differentiation syndrome. For a drug that stimulates platelet production, the absence of clotting complications is a particularly important signal, since raising platelet counts in cancer patients could theoretically tip the balance toward thrombosis.

The study also uncovered intriguing patterns in who responded best. Within the female cohort, patients with tumors of the female reproductive system responded significantly more poorly than those with other cancers: their overall response rate was 57.1 percent compared with 100.0 percent for non-FRS tumors (P = 0.038), and none of the FRS tumor patients achieved a complete response versus 70.0 percent of the others (P = 0.008). The authors also noted trends toward inferior complete response rates among patients with a history of radiotherapy (P = 0.057) and those treated with paclitaxel (P = 0.054), neither of which reached statistical significance in this small sample. These signals suggest that the biology of refractory CTIT may differ depending on the tumor type and prior treatment exposures, and that certain patient groups may need alternative or intensified strategies.

One of the most mechanistically revealing findings involved the bone marrow itself. Patients whose baseline bone marrow biopsies showed higher megakaryocyte counts, at least five per high-powered field, exhibited a trend toward higher overall response rates compared with those with lower counts, 76.5 percent versus 54.5 percent, though the difference did not reach statistical significance (P = 0.41). The observation makes biological sense: megakaryocytes are the cellular factories of platelets, and a marrow that retains a reasonable supply of these cells is more likely to respond to drugs that push them into overdrive. Conversely, patients whose marrows have been devastated by chemotherapy or radiotherapy may lack the raw cellular substrate needed for any platelet-boosting strategy to succeed. If confirmed in larger cohorts, megakaryocyte counts could help clinicians identify which refractory patients are most likely to benefit from the ATRA-plus-TPO-RA combination before committing to six weeks of therapy.

The study’s design demands careful interpretation. As a retrospective, single-center analysis of 28 patients, it cannot rule out selection bias, and without a randomized control group it is impossible to say with certainty how many patients would have recovered on continued TPO-RA monotherapy alone. The authors themselves frame the work as hypothesis-generating. Nevertheless, the magnitude and tempo of the platelet recoveries, the near-complete absence of serious toxicity, and the internal consistency of the response kinetics give the findings considerable weight. A prospective randomized trial will be needed before the combination can be recommended as standard of care, but for a population with essentially no good options, the bar for moving forward is low.

The broader significance extends beyond one drug pairing. CTIT is becoming an increasingly visible problem as cancer therapy grows more intensive and as patients live longer with advanced disease, and refractory cases consume transfusion resources while delaying tumor-directed treatment. The Peking University study suggests that rational combinations of agents targeting different nodes of thrombopoiesis, in this case retinoid-driven megakaryocyte maturation layered on top of thrombopoietin receptor stimulation, can rescue patients who were previously written off. It also revives interest in ATRA, a decades-old leukemia drug, as a repurposed agent in supportive oncology. If larger trials confirm these results, a cheap oral vitamin A derivative could become a standard partner for platelet-boosting drugs, keeping cancer treatment on schedule for thousands of patients whose platelets, and whose therapies, currently run out of road.

Subject of Research: Combination therapy with all-trans retinoic acid and thrombopoietin receptor agonists for refractory cancer therapy-induced thrombocytopenia

Article Title: All-trans retinoic acid combined with thrombopoietin receptor agonists for refractory cancer therapy-induced thrombocytopenia: a retrospective single-center study

Article References: Wang, L.-Y., Gao, H.-T., Fu, Q., Xu, L.-P., Zhang, X.-H., Huang, X.-J., & Tang, F.-F. (2026). All-trans retinoic acid combined with thrombopoietin receptor agonists for refractory cancer therapy-induced thrombocytopenia: a retrospective single-center study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07287-4

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07287-4

Keywords: all-trans retinoic acid, thrombopoietin receptor agonists, cancer therapy-induced thrombocytopenia, platelets, megakaryocytes, solid tumors, hematology, chemotherapy toxicity, Peking University, retrospective study, thrombopoiesis, drug safety

The study, conducted by Ningning Ma of the Department of Sociology at Peking University, analyses the public defence speeches required of finalists for a prestigious undergraduate award at a leading Chinese research university. Using qualitative narrative analysis, Ma treats these speeches not as incidental ceremony but as the decisive mechanism through which student achievement is converted into institutional legitimacy. The findings suggest that in elite higher education, being excellent is not enough; a student must also be able to tell a particular kind of story about how that excellence came to be.

Across disciplines and across the seven years of speeches examined, Ma found that candidates relied on a strikingly consistent narrative arc. The story almost always begins with struggle, ordinariness, or even failure: an unremarkable entrance, early academic difficulty, or a period of uncertainty. What follows is a transformation, achieved not through raw talent alone but through institutional opportunities, mentorship, and structured cultivation provided by the university. The arc concludes with certified achievement, typically marked by international publications, conference presentations, and overseas exchange experiences. Excellence, in this telling, is the outcome of a journey that the institution itself made possible.

This framing has significant implications for how merit is understood. Rather than presenting ability as innate or self-generated, finalists consistently positioned themselves as products of institutional cultivation. The university appears in these narratives as the enabling environment without which individual potential would never mature into recognised accomplishment. In doing so, candidates simultaneously demonstrate humility and affirm the value of the very institution judging them, a rhetorical move that aligns the award winner’s success with the university’s own mission and reputation.

Yet the study shows that listing achievements is not sufficient on its own. International publications, conferences, and study-abroad experiences featured prominently in nearly every defence speech, but candidates rarely presented them as ends in themselves. Instead, these markers of global academic mobility were consistently reframed through narratives of responsibility, contribution, and public value. A publication became evidence of a commitment to advancing knowledge for society; an overseas exchange became a story of bringing back perspectives to serve the home country and community. The evaluative logic, Ma argues, rewards not only demonstrated capability but the ability to present oneself as reliable, socially responsible, and institutionally aligned.

Ma develops the concept of narrative certification to describe this process. Award defences, in this view, function as institutional rituals of certification, comparable in analytical terms to the rituals of verification that scholars of audit culture have identified in universities worldwide. Through the defence, three qualities are validated: cultivability, meaning the candidate can be shown to have been shaped and improved by the institution; comparability, meaning achievements can be ranked and judged against those of peers; and reliability, meaning the candidate can be trusted to embody the values the institution wishes to project. Only trajectories that satisfy these three conditions become recognisable as legitimate forms of excellence.

The concept draws on a rich theoretical tradition. Ma’s analysis engages with Foucauldian ideas of discipline and governmentality, in which subjects are shaped to govern themselves according to institutional norms, and with sociological work on audit culture and rankings, which has shown how public measures do not simply describe social worlds but actively recreate them. Just as university rankings change the behaviour of the institutions they measure, the scholarship defence changes the kinds of students the university produces, encouraging candidates to internalise and perform the narrative forms that the evaluation process rewards.

One of the study’s most notable findings concerns humanities and social science students. Although they were well represented among the finalists, their recognition often depended on demonstrating instrumental relevance and broader social contribution. In an evaluation environment dominated by metrics designed with the natural sciences in mind, such as international publications and conference participation, students in less quantifiable fields had to work harder to translate their achievements into the shared narrative currency of public value. Their success in the defence process, Ma suggests, reveals how institutional recognition can quietly discipline entire disciplines into adopting the evaluative frames of more metric-friendly fields.

The research also situates the Chinese case within the global rise of world-class university projects. Scholars have long debated how elite universities in East Asia blend Confucian traditions of moral cultivation with Western models of research excellence and global competition. The defence speeches analysed in this study embody that blend: candidates celebrate international visibility and global metrics while simultaneously framing their achievements as service to national and social purposes. The result is a distinctive model of excellence in which global ambition and public responsibility are narrated as inseparable, reflecting broader tensions and aspirations in Chinese higher education policy.

Methodologically, the study demonstrates the value of treating institutional documents as active social artefacts rather than passive records. By analysing publicly available defence speeches over seven years, Ma captures a recurring, formalised performance whose conventions remain stable across cohorts of students. Because the study relies on public institutional materials and involves no direct interaction with human participants, it also raises relatively few ethical concerns, while offering a template for researchers elsewhere who wish to examine how their own institutions certify merit. The broader lesson extends well beyond a single Chinese university: wherever scholarships, prizes, and honours are awarded through formal defence or interview processes, excellence is being narratively constructed, and understanding those narratives is essential to understanding how elite status is made, maintained, and legitimised in modern higher education.

Subject of Research: Narrative certification of student excellence in scholarship defence processes at an elite Chinese university

Article Title: Producing legible excellence: narrative certification in an elite Chinese university’s scholarship defence

Article References: Producing legible excellence: narrative certification in an elite Chinese university’s scholarship defence. (n.d.). https://doi.org/10.1007/s10734-026-01760-9

Image Credits: AI Generated

DOI: 10.1007/s10734-026-01760-9

Keywords: narrative certification, higher education, elite universities, audit culture, scholarship defence, elite formation, world-class universities, China, student evaluation, academic excellence, Peking University, qualitative narrative analysis